

Eliminating TB as a public health problem

THE TB CHALLENGE

Tuberculosis (TB) remains a major global health challenge. In 2024, an estimated 10.7 million people fell ill with TB and approximately 1.23 million died from the disease, including around 150 000 people living with HIV. TB is among the top 10 causes of death worldwide and the leading cause of death from a single infectious pathogen.¹

Consequently, new and more effective drugs and shorter, safer treatment regimens — and their rapid uptake — remain urgently needed. Without accelerated innovation and improved treatment strategies, the world is unlikely to meet the World Health Organization's End TB Strategy targets of a 95% reduction in TB deaths and a 90% reduction in TB incidence by 2035.

UNITE4TB

With 30 partners from 13 countries, UNITE4TB aims to accelerate and improve the clinical evaluation of novel compounds and drug combinations to develop new and effective anti-TB treatments for drug-resistant and drug-sensitive TB.

Our vision is to catalyze a sustained, global effort — in collaboration with centres of excellence worldwide — that drives continued investment in TB drug development and helps make the elimination of TB as a public health problem a reality.

“UNITE4TB aims to deliver more effective and shorter regimens through innovative clinical trial designs that conform to the highest regulatory standards.”



Derek Sloan
UNITE4TB Project Lead, Radboudumc

“It's encouraging to see this promising innovative initiative that could make the world of difference for people affected by TB who struggle to get the right medications in the right combinations at the right price. UNITE4TB gives people affected by TB hope!”



Blessina Kumar, UNITE4TB Community Advisory Group member

